Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 205.55

-1.3%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (15075)	2/14/1998 2:43:00 PM
From: Henry Niman	Read Replies (1) of 32384

Andy, I suspect that more is known about the translation from rats to humans, and maybe everyone will know after the ASCO meeting in May. The same animal model has been used to test Panretin and Tamoxifen for chemoprevention in 1994 and I strongly suspect that the positive results led to the two ongoing Phase I trails involving Panretin and Tamoxifen. Since the RXR activating activity seems to be responsible for the in vivo effect, I would expect better results for Targretin than Panretin (and probably better results for LGD1268 than Targretin). Since both Phase I trials were started many (12?) months ago, I suspect that some of the clinical data is known (and will be presented at ASCO). I also suspect that these results are pushing LGND's Phase II breast cancer schedule and it is why employees think the stock price is far too cheap.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next